2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-B0025
    Voglibose 83480-29-9 98.0%
    Voglibose is an orally active alpha-glucosidase inhibitor that prevents the development of colorectal precancerous lesions induced by obesity and diabetes. Voglibose reduces oxidative stress in an inflammatory environment and inhibits the insulin-like growth factor/insulin-like growth factor-1 receptor (IGF/IGF-1R) functional axis.
    Voglibose
  • HY-B0148
    Risedronic acid 105462-24-6 ≥98.0%
    Risedronic acid (Risedronate) is a bisphosphonate and potent antiresorptive agent. Risedronic acid induces Apoptosis. Risedronic acid inhibits the transfer of farnesyl pyrophosphate groups to parasite proteins. Risedronic acid inhibits osteoclast-mediated bone resorption and alters bone metabolism. Risedronic acid inhibits blood-stage Plasmodium falciparum (IC50 of 20.3 μM).
    Risedronic acid
  • HY-B1513
    α-Cyclodextrin 10016-20-3 99.96%
    α-Cyclodextrin (α-CD) is a soluble fiber derived from corn. α-Cyclodextrin can deplete sphingolipids and phospholipids from cell membranes. α-Cyclodextrin interacts with tubulin. α-Cyclodextrin improves defenses against SARS-CoV-2 infection. α-Cyclodextrin enhances the anticancer efficacy of Crcumin (HY-N0005) against breast, lung and cervical cancer. α-Cyclodextrin has beneficial effects on body weight and blood lipids.
    α-Cyclodextrin
  • HY-B2188
    S-Methyl-L-cysteine 1187-84-4 98.0%
    S-Methyl-L-cysteine is a natural product that acts as a substrate in the catalytic antioxidant system mediated by methionine sulfoxide reductase A (MSRA), with antioxidative, neuroprotective, and anti-obesity activities.
    S-Methyl-L-cysteine
  • HY-D1435
    Oxonol VI 64724-75-0 98.18%
    Oxonol VI is an optical indicator of membrane potential in lipid vesicles (excitation/emission wavelengths: 614/646 nm). Oxonol VI can be used to detect changes in membrane potential associated with (Na+ + K+)-ATPase activity in reconstituted vesicles.
    Oxonol VI
  • HY-D1459
    BODIPY 665/676 164106-16-5 99.96%
    BODIPY 665/676 is a lipophilic radical-sensitive fluorescent probe that can be used to study radical-driven lipid autoxidation (Ex/Em=665/676 nm).
    BODIPY 665/676
  • HY-N0327
    Lobetyolin 129277-38-9 ≥98.0%
    Lobetyolin, a bioactive compound, is derived from Codonopsis pilosula. Lobetyolin has anti-inflammatory, anti-oxidative and xanthine oxidase inhibiting activities. Lobetyolin also induces the apoptosis via the inhibition of ASCT2-mediated glutamine metabolism. Lobetyolin is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Lobetyolin
  • HY-N2534
    Karanjin 521-88-0 99.96%
    Karanjin is an orally active furanoflavonoid which can be isolated from several Leguminosae. Karanjin exhibits evident anti-diabetic, anti-cancer, anti-inflammatory, antioxidant, anticolitis, anti-ulcer, anti-Alzheimer properties and multiple insect repellent/insecticidal, acaricide properties, suggesting the potential of Karanjin to be applied to relevant research.
    Karanjin
  • HY-N3021
    D-chiro-Inositol 643-12-9 98.0%
    D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome.
    D-chiro-Inositol
  • HY-N6677
    β-​Apo-​8'-​carotenal 1107-26-2
    β-Apo-8'-carotenal (Apocarotenal), an orally active provitamin A carotenoid. β-Apo-8'-carotenal can induce the expression of CYP1A through the Ah receptor-dependent pathway. β-Apo-8'-carotenal can induce cancer cells DNA strand breaks and lipid peroxidation. β-Apo-8'-carotenal can be used for the researches of cancer and metabolic disease.
    β-​Apo-​8'-​carotenal
  • HY-P1160
    Bay 55-9837 463930-25-8 99.56%
    Bay 55-9837 is a potent and highly selective agonist of VPAC2, with a Kd of 0.65 nM. Bay 55-9837 may be a useful therapy for the research of type 2 diabetes.
    Bay 55-9837
  • HY-P2838
    Creatininase, Microorganism 9025-13-2
    Creatininase, Microorganism (Creatinine amidohydrolase; CAH), namely creatinine amidohydrolase, from Pseudomonas putida, is a homohexameric enzyme commonly used in biochemical research. Creatininase acts on carbon-nitrogen bonds other than peptide bonds, and can catalyze the hydrolysis of creatinine to creatine, which can then be metabolized by creatinase to urea and sarcosine.
    Creatininase, Microorganism
  • HY-P3366
    Ecnoglutide 2459531-73-6 99.93%
    Ecnoglutide (XW003) is a long-acting, cAMP-biased glucagon-like peptide 1 (GLP-1) receptor agonist. Ecnoglutide can be used for research of T2DM and obesity.
    Ecnoglutide
  • HY-109555
    Insulin glulisine 207748-29-6
    Insulin glulisine (HMR 1964) is a rapid-acting insulin analog whose pharmacokinetic and pharmacodynamic properties mimic physiological insulin secretion in humans, with a rapid onset of action. Insulin glulisine controls hyperglycemia. Insulin glulisine is applicable to research related to type 1 diabetes and type 2 diabetes.
    Insulin glulisine
  • HY-113284
    Succinyladenosine 4542-23-8 ≥98.0%
    Succinyladenosine, the metabolic product of dephosphorylation of intracellular adenylosuccinic acid (S-AMP) by cytosolic 5-nucleotidase, is a biochemical marker of adenylosuccinase (ASL) deficiency.
    Succinyladenosine
  • HY-116797
    MS15203 73912-52-4 99.40%
    MS15203 is a potent and selective GPR171 agonist. MS15203 increases food intake and body weight. MS15203 increases neuronal activity. MS15203 significantly increases the abundance of the mRNAs encoding proSAAS, NPY, AgRP.
    MS15203
  • HY-119222
    GSK256073 862892-90-8 99.39%
    GSK256073 is a potent, selective and orally active GPR109A agonist and a long-lasting and non-flushing HCA2 full agonist with a pEC50 of 7.5 (human HCA2). GSK256073 acutely improves glucose homeostasis via inhibition of lipolysis and has the potential for the study of type 2 diabetes mellitus (T2DM)and dyslipidemia. GPR109A: G-protein coupled receptor 109A; HCA2: hydroxy-carboxylic acid receptor 2
    GSK256073
  • HY-120657
    9-PAHSA 1481636-31-0 99.88%
    9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease.
    9-PAHSA
  • HY-122051
    AC1903 831234-13-0 99.69%
    AC1903 is a specific and selective inhibitor of TRPC5 and has podocyte-protective properties. AC1903 does no effects on TRPC4 or TRPC6 currents and shows no off-target effects in kinase profiling assays. AC1903 suppresses severe proteinuria and prevents podocyte loss in focal segmental glomerulosclerosis (FSGS) rat model.
    AC1903
  • HY-125848
    Ginsenoside F2 62025-49-4 99.92%
    Ginsenoside F2 is an orally active bioactive compound that participates in the regulation of metabolism and inflammation. Ginsenoside F2 promotes the phosphorylation of AMPK and ACC, binds to PPARγ, inhibits the phosphorylation of MAPK, activates the PI3K/AKT/GSK-3β pathway, reduces GLRX expression, and regulates lipid metabolism. Ginsenoside F2 reduces ROS production and MDA levels, restores SOD activity in cells, and alleviates oxidative stress. Ginsenoside F2 induces cell apoptosis (Apoptosis) and increases the number of cleaved caspase-3-positive cells. Ginsenoside F2 reduces body weight gain, adipose tissue weight and serum lipid levels in obese mice, and activates the hepatic AMPK signaling pathway and the expression of antioxidant enzymes. Ginsenoside F2 alleviates atopic dermatitis in mice by inhibiting inflammation and reshaping the gut microbiota. Ginsenoside F2 is applicable to research related to insulin resistance, obesity, atopic dermatitis, liver cancer, glioblastoma and glioma.
    Ginsenoside F2
Cat. No. Product Name / Synonyms Application Reactivity